BACKGROUND: Approximately 105 000 cardiac electronic devices are newly implanted in Germany each year. Germany has the highest implantation rate with respect to population of any European country. Infections in cardiac implants are serious complications, with an associated in-hospital mortality of 5-15%. It is thus very important to optimize the diagnostic and therapeutic strategies by which such infections can be detected early and treated effectively. METHODS: This review is based on pertinent publications retrieved by a search in PubMed, with special attention to the current recommendations of international medical specialty societies. RESULTS: According to the international literature, the incidence of device-associated infection is 1.7% (in six months) for implanted defibrillators and 9.5% (in two years) for resynchronization devices. No absolute figures on infection rates are available for Germany. Infection can involve either the site where the impulse generator is implanted or the intravascular portion of the electrodes. The most important elements of the diagnostic evaluation are: assessment of the local findings; pathogen identification by culture of peripheral blood, swabs of the infected site, or material recovered at surgery; and transesophageal echocardiography to detect endocarditic deposits on the electrodes or cardiac valves. The treatment consists of appropriate antibiotic administration and the complete removal of all foreign material. These special extractions are generally performed via the transvenous route. With the aid of various sheath systems, the procedure can be carried out safely and effectively, with a success rate above 95% and a complication rate below 3%. The indications for the implantation of a new device after eradication of the infection should be critically reassessed. CONCLUSION: Untreated infection carries a high mortality. Evaluation and treatment according to a standardized clinical algorithm facilitate correct and timely diagnosis and the choice of an appropriate therapeutic strategy.
BACKGROUND: Approximately 105 000 cardiac electronic devices are newly implanted in Germany each year. Germany has the highest implantation rate with respect to population of any European country. Infections in cardiac implants are serious complications, with an associated in-hospital mortality of 5-15%. It is thus very important to optimize the diagnostic and therapeutic strategies by which such infections can be detected early and treated effectively. METHODS: This review is based on pertinent publications retrieved by a search in PubMed, with special attention to the current recommendations of international medical specialty societies. RESULTS: According to the international literature, the incidence of device-associated infection is 1.7% (in six months) for implanted defibrillators and 9.5% (in two years) for resynchronization devices. No absolute figures on infection rates are available for Germany. Infection can involve either the site where the impulse generator is implanted or the intravascular portion of the electrodes. The most important elements of the diagnostic evaluation are: assessment of the local findings; pathogen identification by culture of peripheral blood, swabs of the infected site, or material recovered at surgery; and transesophageal echocardiography to detect endocarditic deposits on the electrodes or cardiac valves. The treatment consists of appropriate antibiotic administration and the complete removal of all foreign material. These special extractions are generally performed via the transvenous route. With the aid of various sheath systems, the procedure can be carried out safely and effectively, with a success rate above 95% and a complication rate below 3%. The indications for the implantation of a new device after eradication of the infection should be critically reassessed. CONCLUSION: Untreated infection carries a high mortality. Evaluation and treatment according to a standardized clinical algorithm facilitate correct and timely diagnosis and the choice of an appropriate therapeutic strategy.
Authors: Arnold J Greenspon; Jasmine D Patel; Edmund Lau; Jorge A Ochoa; Daniel R Frisch; Reginald T Ho; Behzad B Pavri; Steven M Kurtz Journal: J Am Coll Cardiol Date: 2011-08-30 Impact factor: 24.094
Authors: A L Chamis; G E Peterson; C H Cabell; G R Corey; R A Sorrentino; R A Greenfield; T Ryan; L B Reller; V G Fowler Journal: Circulation Date: 2001-08-28 Impact factor: 29.690
Authors: Katherine Y Le; Muhammad R Sohail; Paul A Friedman; Daniel Z Uslan; Stephen S Cha; David L Hayes; Walter R Wilson; James M Steckelberg; Larry M Baddour Journal: Heart Rhythm Date: 2011-05-27 Impact factor: 6.343
Authors: Jordan M Prutkin; Matthew R Reynolds; Haikun Bao; Jeptha P Curtis; Sana M Al-Khatib; Saurabh Aggarwal; Daniel Z Uslan Journal: Circulation Date: 2014-07-31 Impact factor: 29.690
Authors: Larry M Baddour; Andrew E Epstein; Christopher C Erickson; Bradley P Knight; Matthew E Levison; Peter B Lockhart; Frederick A Masoudi; Eric J Okum; Walter R Wilson; Lee B Beerman; Ann F Bolger; N A Mark Estes; Michael Gewitz; Jane W Newburger; Eleanor B Schron; Kathryn A Taubert Journal: Circulation Date: 2010-01-04 Impact factor: 29.690
Authors: Tanja Kuecken; Ruta Jasaityte; Cara Bülow; Jessica Gross; Anja Haase-Fielitz; Michael Neuss; Christian Butter Journal: Front Cardiovasc Med Date: 2022-06-14
Authors: Joop J P Kouijzer; Daniëlle J Noordermeer; Wouter J van Leeuwen; Nelianne J Verkaik; Kirby R Lattwein Journal: Front Cell Dev Biol Date: 2022-10-03